Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Acetaminophen effects on developing brain organoids; and more
Here is a roundup of autism-related news and research spotted around the web for the week of 12 October.
Acetaminophen effects on developing brain organoids; and more
Here is a roundup of autism-related news and research spotted around the web for the week of 12 October.
Private initiative makes ‘historic’ investment in autism research
Aligning Research to Impact Autism has committed more than $450 million to build a new multidisciplinary research network to uncover the roots of profound autism and develop treatments.
Private initiative makes ‘historic’ investment in autism research
Aligning Research to Impact Autism has committed more than $450 million to build a new multidisciplinary research network to uncover the roots of profound autism and develop treatments.
The neural code at 100
In two 1926 articles, Edgar Douglas Adrian revealed that neurons communicate through trains of spikes.
The neural code at 100
In two 1926 articles, Edgar Douglas Adrian revealed that neurons communicate through trains of spikes.